Depletion of METTL3/METTL14 using CRISPR/Cas9 gene editing technology sensitizes CRC cells and melanoma cells to anti-PD-1 therapy, and exhibits a synergetic effect by prolonging overall survival [98]. Here, METTL14 is linked to colorectal carcinoma.